

CIN No:- L24230PB2006PLC030341
GST No:- 02AAHCA5390H2ZT



Ref. No.

Date...12/11/2020

To

Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Ref: BSE Security Code 540694

Sub: Outcome of Board Meeting pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors in its meeting held on 12th November, 2020 has considered and approved the Standalone Un-Audited Financial Results of the Company for the Half year ended 30th September, 2020 along with Statement of Assets and Liabilities and Cash Flow Statement as at 30th September, 2020.

Please find enclosed herewith the copy of same together with the Limited Review Report thereon issued by M/s Ajay K Khanna & Co., Statutory Auditors of the Company.

The Board Meeting was commenced at 4:00 P.M and concluded at 5:15 P.M.

This is for your information. Kindly take the same on your record.

Thanking You,

Yours Faithfully

For **ANG Lifesciences India Limited**


Preeti Goel
Company Secretary & Compliance Officer

Factory:

Village: Kishanpura,
Nalagarh Road,
Tehsil: Baddi,
Distt.: Solan,
HP-174101

Regd. Office : SCO-113,
DARBARA COMPLEX,
First Floor, B-BLOCK,
Ranjit Avenue, Amritsar.
Ph. 0183-5133455, 5133458
E mail :- operations@anglifesciences.com
website : www.anglifesciences.com

ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED 30TH
SEPTEMBER, 2020**

(In Lacs)

Particulars	Half Year Ended			For the year ended	Previous Year Ended
	30.09.2020	31.03.2020	30.09.2019	31.03.2020	31.03.2019
	Unaudited	Audited	Unaudited	Audited	Audited
I. Revenue from operations	8612.755	6820.130	5862.990	12683.120	12169.980
II. Other income	42.838	29.400	12.570	41.970	23.270
III. Total Revenue (I + II)	8655.593	6849.530	5875.560	12725.090	12193.250
IV. Expenses:					
(a) Cost of materials consumed	5971.341	4683.610	4272.070	8955.680	8888.650
(b) Changes in Inventories	136.657	-115.670	56.900	-58.770	-104.550
(c) Employee benefits expense	603.887	525.930	267.700	793.630	639.130
(d) Finance costs	142.250	137.880	148.860	286.740	234.270
(e) Depreciation and amortization expense	56.348	68.040	54.830	122.870	112.370
(f) Other expenses	1010.317	1105.750	678.570	1784.320	1612.510
Total expenses	7920.800	6405.540	5478.930	11884.470	11382.380
V. Profit before exceptional and extraordinary items and tax (III-IV)	734.793	443.990	396.630	840.620	810.870
VI. Exceptional items	0.000	0.000	0.000	0.000	0.000
VII. Profit before extraordinary items and tax (V - VI)	734.793	443.990	396.620	840.620	810.870
VIII. Extraordinary Items	0.000	0.000	0.000	0.000	0.000
IX. Profit before tax (VII- VIII)	734.793	443.990	396.630	840.620	810.870
X Tax expense:					
(1) Current tax	185.100	127.650	112.350	240.000	236.530
(2) Deferred tax	-0.525	-8.820	-0.120	-8.940	2.740
(3) Mat Credit Entitlement	0.000	0.000	0.000	0.000	6.700
XI Profit (Loss) for the period from continuing operations (VII-VIII)	550.218	325.160	284.400	609.560	564.900
XII Profit/(loss) from discontinuing operations	0.000	0.000	0.000	0.000	0.000
XIII Tax expense of discontinuing operations	0.000	0.000	0.000	0.000	0.000
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.000	0.000	0.000	0.000	0.000



XV	Profit (Loss) for the period (XI + XIV)	550,218	325,160	284,400	609,560	564,900
XVI	Earnings per equity share:					
	(a) Basic & Diluted (Rs.)	10.615	6.273	5.487	11.760	10.90
	(b) Diluted (Rs.)	10.62	6.27	5.49	11.76	10.90

Notes :

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on November 12, 2020.
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4) The figures for the half year ended 31st March 2020 are the balancing figures between the audited figures of full financial year 31st March 2020 and half year ended 30th September, 2019.
- 5) As per MCA Notification dated 16.02.2015, the Companies whose shares are listed on SME Exchange as referred in Chapter XB of SEBI (Issue of Capital Disclosure requirements) Regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 6) There were no Investors complaints pending as on 30.09,2020.

For ANG Life Sciences India Limited


 (Managing Director)
 Rajesh Gupta
 (DIN : 01423407)

Date : 12.11.2020

Place : Amritsar

ANG Life Sciences India Ltd.
CIN : L24230PB2006PLC030341
Registered Office : 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar
Email ID : cs@anglifesciences.com
Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the half year ended	For the year ended
		30.09.2020	31.03.2020
I.	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) <u>Share capital</u>	518.332	518.332
	(b) <u>Reserves and surplus</u>	3487.433	2937.215
	Sub-total-Shareholders' Fund	4005.764	3455.547
2	Non-current liabilities		
	(a) <u>Long-term borrowings</u>	595.862	524.997
	(b) <u>Other Long-term liabilities</u>	285.130	286.208
	(c) <u>Deferred Tax Liabilities (Net)</u>	30.231	30.756
	(d) <u>Long-term Provisions</u>	20.927	20.312
	Sub-total-non Current Liabilities	932.150	862.273
3	Current liabilities		
	(a) <u>Short Term Borrowings</u>	1601.633	1291.938
	(b) <u>Trade Payables</u>		
	<u>Due to Micro, Small & Medium Enterprise</u>	522.355	443.061
	<u>Due to Others</u>	2388.378	2135.902
	(c) <u>Other current liabilities</u>	1149.520	978.794
	(d) <u>Short-term provisions</u>	425.100	240.000
	Sub-total-Current Liabilities	6086.986	5089.695
	TOTAL EQUITY AND LIABILITIES	11024.901	9407.514
II.	ASSETS		
	Non-current assets		
1	(a) <u>Property, Plant and Equipment</u>		
	(i) <u>Tangible assets</u>	2093.357	2093.732
	(ii) <u>Intangible assets</u>	23.119	23.119
	(b) <u>Other non-current Investments</u>	2.000	2.000
	(c) <u>Deferred Tax Assets (Net)</u>	0.000	0.000
	(d) <u>Long-term loans and advances</u>	0.000	0.000
	(e) <u>Other non-current assets</u>	12.371	17.371
	Sub-total-non Current Assets	2130.846	2136.221
2	Current assets		
	(a) <u>Current Investments</u>	0.000	0.000
	(b) <u>Inventories</u>	745.362	1000.430
	(c) <u>Trade receivables</u>	6220.731	4606.416
	(d) <u>Cash and cash equivalents</u>	328.347	360.055
	(e) <u>Short-term loans and advances</u>	794.182	725.143
	(f) <u>Other Current Assets</u>	805.434	579.246
	Sub-total-Current Assets	8894.055	7271.290
	TOTAL ASSETS	11024.901	9407.511
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited



ANG Life Sciences India Ltd.
R.O. 113, First Floor, Darbara Complex,
Ranjit Avenue, Amritsar

CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2020

	Particulars	As at 30 September 2020	Year ended 31st March 2020
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
1	Net Profit/(loss) before extraordinary items and Tax	550.22	609.56
2	Adjustments for ;		
a)	Depreciation and Amortisation	56.35	122.87
b)	Finance Cost Expenses	142.25	286.74
c)	Current Taxes	185.10	240.00
d)	Deferred Taxes	-0.52	-8.94
e)	Premininary Expenses	0.00	0.00
f)	MAT Credit	0.00	0.00
	Operating Profit before working capital Changes (1+2)	933.39	1250.23
3	Adjustments for Working Capital Changes ;		
(i)	(Increase)/decrease Operating Assets		
a)	Trade Receivables	-1614.31	-43.16
b)	Short Term Loans and Advances	-69.04	-526.16
c)	Other Current Assets	-226.19	-48.08
		0.00	0.00
		0.00	0.00
(ii)	Increase/(Decrease) in Operating Liabilities	0.00	0.00
a)	Trade Payables	331.77	397.50
b)	Short Term Provisions	185.10	20.00
c)	Other Current Liabilities	170.73	381.27
d)	Other Long Term Liability	-1.08	-3.87
e)	Long Term Provisions	0.62	5.25
f)	Short Term Borrowings	309.70	50.49
		0.00	0.00
(iii)	(Increase)/Decrease in inventories	255.07	-346.70
		275.75	748.39
	Less : Income Tax Paid (Net)	-185.10	-265.32
	Net Cash from Operating Activities (A)	90.65	483.07
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
a)	Purchase of Fixed Assets including Capital W.I.P.	-55.97	-164.21
b)	Change in Non-Current Assets	5.00	-1.45
c)	Change in Non-Current Investment		0.00
	Net Cash from Investing Activities (B)	-50.97	-165.66



(C)	CASH FLOW FROM FINANCING ACTIVITIES		
a)	Interest paid	-142.25	-286.74
b)	Proceeds from Long Term Borrowings	316.90	172.50
c)	Repayment of Long Term Borrowings	-246.04	-275.27
d)	Proceeds from issue of Share Capital	0.00	0.00
e)	Proceeds from Share Premium	0.00	0.00
f)	Proceeds from sale of assets	0.00	0.00
g)	Decrease in Capital Reserve	0.00	-5.00
	Net Cash from Financing Activities (C)	-71.39	-394.51
(D)	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	-31.71	-77.09
(E)	Cash & Cash Equivalents at the beginning of the year	360.05	437.15
(F)	Cash & Cash Equivalents at the end of the year	328.35	360.05

Note : 1 Components of Cash & Cash Equivalents

Cash in hand

Balance with Schedule Banks

in Current Accounts

2. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the Accounting Standard-3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India

3. The previous year's figures have been regrouped wherever necessary.

As per our report attached of even date
For ANG Life Sciences India Limited •


(Managing Director)
Rajesh Gupta
(DIN : 01423407)

Date : 12.11.2020

Place : Amritsar



**INDEPENDENT AUDITORS LIMITED REVIEW REPORT ON THE UNAUDITED FINANCIAL
RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2020**

Review Report to
The Board of Directors,
ANG Lifesciences India Limited
SCO 113, Darbara Complex,
First Floor, B-Block,
Ranjit Avenue, Amritsar-143001

We have reviewed the accompanying statement of unaudited financial results of **ANG Lifesciences India Limited** for the half year ended on 30th September, 2020. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ajay K Khanna & Co.
Chartered Accountants



(Bhupinder Singh)
Partner
M. No. 513899
FRN: 012303N
UDIN: 20513899AAAAHQ9567
Place: Amritsar
Date: 12.11.2020